Vertex Pharmaceuticals Incorporated
NASDAQ:VRTXBiotechnology
-$6.43 today
- Market cap
- $136.01B
- Beta
- 0.31
- P/E (TTM)
- 26.5
- EPS (TTM)
- $17.07
Volume 1.29M
Average 1.26M
VRTX Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Vertex Pharmaceuticals IncorporatedNASDAQ: VRTX
Accounts Payables · Q2 FY2026 · quarter ended Jun 2026
Accounts payables turns negative
Q2 FY2026 accounts payables was -$66.7M, compared with $7.6M a year earlier. Trailing-twelve-month accounts payables was -$28.1M. Over 3 fiscal years it compounded at -32.7% a year.
Context
- Accounts payables amounted to 0.3% of revenue in FY2025, down 0.1 pp from a year earlier.
- Accounts payables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts payables holds near -$66.7M or moves back toward the trailing-twelve-month quarterly average of -$7.03M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 36.8M USD
- Year-over-year change
- -25.7%
- 4-year CAGR
- +3.6%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 36.8M | -25.7% |
| FY2024 | 2024-12-31 | 49.5M | +1.6% |
| FY2023 | 2023-12-31 | 48.7M | -59.7% |
| FY2022 | 2022-12-31 | 120.8M | +278.7% |
| FY2021 | 2021-12-31 | 31.9M | — |
Accounts Payables vs competitors
How VRTX compares with its peers on the latest reported figures
- VRTX's LTM Jun 2026 accounts payables of $28.1M is the 4th largest of the 11 companies compared; the peer median is $2.66M.
- Its year-over-year change of -125.9% is the 8th highest of 10, against a peer median of -42.1%.
- Accounts payables amounts to 0.2% of revenue for VRTX, versus a peer median of 1.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $52.73B | -274455.3% | +3.9% | 5.1% | |
| LTM Jun 2026 | $65.76M | -237.3% | -26.8% | 1.4% | |
| LTM Mar 2026 | $39.15M | -42.1% | -10.9% | 1.8% | |
| LTM Jun 2026 | $28.1M | -125.9% | -32.7% | 0.2% | |
| LTM Mar 2026 | $15.45M | +166.8% | -33.0% | 2.3% | |
| LTM Sep 2026 | $11.71M | -66.8% | — | 1.2% | |
| LTM Mar 2026 | $6.44M | +1108.8% | — | 9.7% | |
| LTM Jun 2026 | $3.04M | -41.5% | +36.5% | 1.9% | |
| LTM Sep 2026 | $2.29M | +190.9% | +105.6% | 9.1% | |
| LTM Jun 2026 | $1.07M | -88.4% | — | 0.1% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding VRTX) | $2.66M | -42.1% | -3.5% | 1.9% | |
Competitors are the stored peer set for VRTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 2.34B | 3.32B | 3.62B | (535.6M) | 3.95B |
| Depreciation & Amortization | 125.6M | 148.3M | 181.3M | 207.2M | 209.8M |
| Deferred Income Tax | (154.6M) | (275.9M) | (536.5M) | (348.8M) | (510.8M) |
| Stock-Based Compensation | 441.4M | 491.3M | 581.2M | 698.5M | 685.9M |
| Change in Working Capital | (105.2M) | 340.8M | (265.7M) | (514.8M) | (1.2B) |
| Accounts Receivables | (274.7M) | (358.6M) | (84.1M) | (99.3M) | (347.3M) |
| Inventory | (92.8M) | (136.4M) | (322.9M) | (517.3M) | (524.2M) |
| Accounts Payables | 31.9M | 120.8M | 48.7M | 49.5M | 36.8M |
| Other Working Capital | 230.4M | 715M | 92.6M | 52.3M | (364.4M) |
| Other Non-Cash Items | (5.8M) | 103.4M | (42.6M) | 900K | 492.4M |
| Operating Cash Flow | 2.64B | 4.13B | 3.54B | (492.6M) | 3.63B |
| Capital Expenditures | (235M) | (204.7M) | (258.4M) | (297.7M) | (437.6M) |
| Acquisitions (Net) | 77M | (295.9M) | 0 | 0 | 0 |
| Purchases of Investments | (605.2M) | (692.7M) | (3.79B) | (7.7B) | (6.4B) |
| Sales of Investments | 499.3M | 920M | 934.2M | 4.47B | 5.91B |
| Other Investing Activities | (77M) | (47.8M) | (89M) | (241.7M) | (24.7M) |
| Investing Cash Flow | (340.9M) | (321.1M) | (3.14B) | (3.77B) | (945.4M) |
| Debt Repayment | (18.7M) | (85.5M) | (44.9M) | (33.6M) | (5.4M) |
| Common Stock Issued | 102M | 186.3M | 134.6M | 114.6M | 127.7M |
| Common Stock Repurchased | (1.43B) | (172M) | (427.6M) | (1.18B) | (2.02B) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (130.2M) | 3.5M | (224.3M) | (398.8M) | (366.2M) |
| Financing Cash Flow | (1.48B) | (67.7M) | (562.2M) | (1.49B) | (2.26B) |
| Effect of Forex Changes | (13.4M) | (29.2M) | 26.9M | (42.6M) | 90.9M |
| Net Change in Cash | 811.2M | 3.71B | (139.7M) | (5.8B) | 515.6M |
| Free Cash Flow | 2.41B | 3.93B | 3.28B | (790.3M) | 3.19B |
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
Intrinsic Alpha fair value
Locked
Current Price
$536.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.